Immunosuppression

NCT00619528
Study Type: Interventional
Study Design: Allocation:Nonrandomized
End Point Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title: HLA-Identical Sibling Renal Transplant Tolerance with Donor Hematopoietic Stem Cells and Campath-1H

Ages Eligible for Study: 18 to 65 years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: Yes

Sponsors and Collaborators
Northwestern University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Contact: Joshua Miller, MD (312) 503-1801 joshuamiller@northwestern.edu